<div id="readability-page-1"><div><p><span>Rothfuss Cristin Vice President of Sarepta Therapeutics Inc [SRPT] filed a Form 4 on December 2, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:</span></p><div><table><tbody><tr><td><span>Date</span></td><td><span>11/28/25</span></td></tr><tr><td><span>Transaction</span></td><td><span>Surrender(1)</span></td></tr><tr><td><span>Shares</span></td><td><span>229</span></td></tr><tr><td><span>Price</span></td><td><span>$21.12</span></td></tr><tr><td><span>Value</span></td><td><span>$4,836</span></td></tr></tbody></table></div><p><span>Ending Holdings: 139,756 - Direct</span></p><ul><li><span>(1)</span></li><li><span>Surrender of shares back to company to pay option exercise cost and/or resulting tax liability.</span></li></ul><p><span>For a free trial, or to learn more about our insider trading analysis and data services, please visit http://www.washingtonservice.com or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.</span></p><p><span>Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.</span></p><span> </span></div></div>

SRPT

<p>Rothfuss Cristin, VP of Sarepta Therapeutics Inc, filed a Form 4 with the SEC on Dec 2, 2025, disclosing the surrender of 229 shares at $21.12 each, valued at $4,836, to cover option exercise costs or tax liabilities. Ending holdings are 139,756 shares directly. The Washington Service offers insider trading analysis and data services.</p>

VP Rothfuss Surrenders 229 Of Sarepta Therapeutics Inc [SRPT]